Mesenchymal stem cells which express TNF-± receptor Type I in an amount of at least 13 pg/ 10 6 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.
